ClinicalTrials.Veeva

Menu

Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients

D

Dr WANG Shumei

Status

Unknown

Conditions

Psychosis
Schizophrenia
Parkinsonism
Dyskinesias

Treatments

Behavioral: RAS for at-risk individuals
Behavioral: No RAS for schizophrenia patients
Behavioral: No RAS for at-risk individuals
Behavioral: Rhythmic auditory stimulation (RAS) for schizophrenia patients

Study type

Interventional

Funder types

Other

Identifiers

NCT04553835
HSEARS20200630002

Details and patient eligibility

About

The purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. The investigators hypothesize that training with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.

Enrollment

60 estimated patients

Sex

All

Ages

13 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

For at-risk individuals:

The inclusion criteria for at-risk individuals are:

  1. A score of or above 9 in the Chinese version of the 16-item Prodromal Questionnaire (CPQ-16), or a score of or above 8.18 in the Chinese version of Community Assessment of Psychic Experiences with 15 items (CAPE-C15), or a score of or above 17 in Schizotypal Personality Questionnaire-Brief (SPQ-B);
  2. A score of or above 22 in the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) to ensure that they can understand instructions;
  3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory to ensure that they are right-handed.
  4. The age ≥ 13 years.

The inclusion criteria for healthy controls are:

  1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B;
  2. A score of or above 22 in MoCA;
  3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory;
  4. No first-degree family members having a diagnosis of mental illnesses.
  5. The age ≥ 13 years.

At-risk participants and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.

For schizophrenia patients:

The inclusion criteria for schizophrenia patients are:

  1. A diagnosis of schizophrenia without other psychiatric diseases;
  2. Having stable psychotic symptoms;
  3. A score of or above 22 in HK-MoCA;
  4. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory.
  5. The age ≥ 18 years.

The inclusion criteria for healthy controls are:

  1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B;
  2. A score of or above 22 in MoCA;
  3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory;
  4. No first-degree family members having a diagnosis of mental illnesses.
  5. The age ≥ 18 years.

Patients and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 4 patient groups

schizophrenia- RAS
Experimental group
Description:
Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
Treatment:
Behavioral: Rhythmic auditory stimulation (RAS) for schizophrenia patients
schizophrenia- no RAS
Active Comparator group
Description:
Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
Treatment:
Behavioral: No RAS for schizophrenia patients
at risk- RAS
Experimental group
Description:
At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
Treatment:
Behavioral: RAS for at-risk individuals
at risk- no RAS
Active Comparator group
Description:
At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
Treatment:
Behavioral: No RAS for at-risk individuals

Trial contacts and locations

1

Loading...

Central trial contact

Shu-Mei Wang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems